CT Cardiomegaly vs InVision Precision Cardiac Amyloid
AI Verdict
Choose CT Cardiomegaly if…
Choose CT Cardiomegaly if your primary need is automated, quantitative measurement of the cardiothoracic ratio from CT chest images. This tool is ideal for radiologists and cardiologists seeking to efficiently screen for general cardiomegaly and obtain precise, objective data to support their diagnostic assessments. It integrates well into existing CT imaging workflows as a command-line software solution.
View CT Cardiomegaly →Choose InVision Precision Cardiac Amyloid if…
Choose InVision Precision Cardiac Amyloid if you require AI-powered assistance for the specific and early detection of cardiac amyloidosis using echocardiography. This software is best suited for echocardiography labs and cardiologists focused on diagnosing this often underdiagnosed disease in patients presenting with heart failure symptoms, aiming to improve patient outcomes through timely intervention.
View InVision Precision Cardiac Amyloid →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CT Cardiomegaly | InVision Precision Cardiac Amyloid |
|---|---|---|
| Pricing | Contact for pricing | Unknown |
| Deployment | Docker Container (Ubuntu 20.04), command-line software | Cloud or on-premise |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
InVision Precision Cardiac AmyloidTool B is designed for seamless integration into clinical workflows for echocardiography labs, aiming for 'zero marginal clinician burden'. In contrast, Tool A is described as 'command-line software' and a 'Docker Container', suggesting a more technical interface requiring IT expertise rather than direct clinical user interaction.
Clinical Value
InVision Precision Cardiac AmyloidTool B addresses the critical need for early detection of cardiac amyloidosis, a life-threatening and often underdiagnosed disease, with strong evidence including peer-reviewed publications in JAMA Cardiology and FDA Breakthrough Device Designation. Tool A provides automated cardiothoracic ratio measurement for cardiomegaly detection, which is valuable but addresses a less complex and less frequently missed diagnosis compared to cardiac amyloidosis.
Pricing & Value
InVision Precision Cardiac AmyloidTool B offers transparent pricing with a clear starting point of '$49/mo' and mentions a CPT Category III code for reimbursement, providing a direct path for financial viability. Tool A's pricing is 'contact for pricing', which offers less upfront transparency and makes it harder to assess immediate value.
Enterprise Readiness
InVision Precision Cardiac AmyloidBoth tools are FDA-cleared and HIPAA compliant, indicating foundational readiness. However, Tool B explicitly focuses on integration into clinical workflows and EHRs, and offers a 'growing suite of cleared algorithms' via a single integration, suggesting a more comprehensive and scalable solution for healthcare systems. Tool A's Docker deployment is robust for IT but less explicitly tailored for broad clinical workflow integration.
Innovation
InVision Precision Cardiac AmyloidTool B demonstrates higher innovation by tackling the complex and often underdiagnosed condition of cardiac amyloidosis, with its algorithm being the 'only FDA cleared diagnostic aid for cardiac amyloidosis even before they have heart failure symptoms'. Its development includes peer-reviewed publication in JAMA Cardiology and FDA Breakthrough Device Designation. Tool A, while valuable, automates a more standard measurement of cardiothoracic ratio.
Support & Docs
InVision Precision Cardiac AmyloidTool B indicates a proactive support model by offering direct briefings to walk through deployment, reimbursement, and evidence tailored to the cardiovascular service line. While Tool A's company, Innolitics, provides technical documentation related to DICOM standards, it does not explicitly detail product-specific user support or documentation for its CT Cardiomegaly tool.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CT Cardiomegaly | InVision Precision Cardiac Amyloid |
|---|---|---|
| Name | CT Cardiomegaly | InVision Precision Cardiac Amyloid |
| Company | Innolitics | InVision Medical Technology Corporation |
| Description | FDA-cleared AI-powered command-line software that automatically measures cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection with quantitative data. | AI-powered software for echocardiography to detect cardiac amyloidosis, a life-threatening and often underdiagnosed disease, aiming for earlier detection and improved patient outcomes. |
| Primary Clinical Focus | Cardiomegaly detection via cardiothoracic ratio measurement | Cardiac amyloidosis detection from echocardiograms |
| Key Features (Selection) | Automatic cardiothoracic ratio measurement, segmentation of heart and thoracic cavity, outputs PDF and JSON reports. | AI-powered detection of cardiac amyloidosis, evaluation of transthoracic echocardiogram studies, aids clinicians in diagnosing and assessing patients with heart failure symptoms. |
Videos
Demos, reviews, and walkthroughs featuring CT Cardiomegaly and InVision Precision Cardiac Amyloid.